The U.S. Food and Drug Administration (FDA) has approved Xocova, a pill designed to prevent COVID-19 infection in individuals aged 12 and older following direct exposure to the virus. Dr. William Schaffner, a professor at Vanderbilt University Medical Center, stated that the medication is intended for use after a person learns they have been exposed to a contact who has tested positive.
The drug, classified as a protease inhibitor, is taken for five days. Clinical trial data indicates that when the medication is started within three days of exposure, the risk of developing COVID-19 is reduced by two-thirds. Physicians noted that while the drug helps prevent infection, it is not a substitute for COVID-19 vaccinations, which remain the primary recommended prevention method.
Xocova is indicated for significant exposures, such as living with an infected person or sharing a workspace, rather than for use before or after attending large public events. Dr. Mark Loafman, a family physician in Chicago, noted that doctors have extensive experience with protease inhibitors for viral treatments. Reported side effects during trials included diarrhea, headache, cough, congestion, and muscle aches.
A person using Xocova would need to contact a healthcare provider for a prescription after exposure to begin the five-day regimen within the three-day window. The medication is intended to either prevent illness entirely or result in a milder, shorter infection. Xocova is currently the only post-exposure prevention pill on the market, though other pharmaceutical companies are developing alternative options such as nasal sprays.
The availability of the pill adds a layer of post-exposure protocol that complements existing measures like masking and handwashing. However, medical professionals emphasize that the availability of this antiviral treatment does not change the recommendation for primary vaccination. Patients must consult their doctors to determine if their specific exposure situation warrants a prescription. Future availability and pricing will depend on assistance programs and insurance negotiations.